Estrogens, Conjugated (USP)
(QTTMOCOWZLSYSV-QWAPEVOJSA-M)
Structure
- SMILES
- O=C1CC[C@@H]2[C@]1(C)CC[C@H]1C2=CCc2c1ccc(c2)OS(=O)(=O)[O-].[Na+]
- Molecular Formula:
- C18H19NaO5S
- Molecular Weight:
- 370.395
- Log P:
- 3.9517
- Hydrogen Bond Acceptor:
- 5
- Hydrogen Bond Donor:
- 0
- TPSA:
- 91.88
- CAS Number(s):
- 16680-47-0
Synonym(s)
1.
Estrogens, Conjugated (USP)
2.
Estrogenic Substances, Conjugated
3.
Carentil
4.
Climarest
5.
Climopax
6.
Congest
7.
Conjugated Equine Estrogens
8.
Conjugated Estrogens
9.
Dagynil
10.
Estro-Feminal
11.
Estrogenic Hormones, Conjugated
12.
Estrogens, Conjugated
13.
Femavit
14.
Oestro-Feminal
15.
Oestrofeminal
16.
Prelestrin
17.
Premarin
18.
Presomen
19.
Progens
20.
Transannon
21.
Conjugated Estrogenic Hormones
22.
Conjugated Estrogenic Substances
23.
Equine Estrogens, Conjugated
24.
Estro Feminal
25.
Oestro Feminal
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Drug ineffective | FAERS: 16 Canada Vigilance: 6 | Canada Vigilance US FAERS | |
| 2 | Invasive Ductal Breast Carcinoma | FAERS: 6 | US FAERS | |
| 3 | Product use in unapproved indication | FAERS: 6 | US FAERS | |
| 4 | Headache | FAERS: 4 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 5 | Anxiety | FAERS: 3 | US FAERS | |
| 6 | Diplopia | FAERS: 3 | US FAERS | |
| 7 | Pruritus | FAERS: 3 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 8 | Abdominal Pain | FAERS: 2 | US FAERS | |
| 9 | Alopecia | FAERS: 2 | US FAERS | |
| 10 | Cerebrovascular accident | FAERS: 2 | US FAERS | |
| 11 | Cholelithiasis | FAERS: 2 | US FAERS | |
| 12 | Dermatitis | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 13 | Drug effect incomplete | FAERS: 2 | US FAERS | |
| 14 | Inappropriate schedule of drug administration | FAERS: 2 | US FAERS | |
| 15 | Malaise | FAERS: 2 | US FAERS | |
| 16 | Portal Vein Thrombosis | FAERS: 2 | US FAERS | |
| 17 | Urticaria | FAERS: 2 | US FAERS | |
| 18 | Vaginal Discharge | FAERS: 2 | US FAERS | |
| 19 | Vomiting | FAERS: 2 | US FAERS | |
| 20 | Acne | FAERS: 1 | US FAERS | |
| 21 | Application site pain | FAERS: 1 | US FAERS | |
| 22 | Atrophic vulvovaginitis | FAERS: 1 | US FAERS | |
| 23 | Back Pain | FAERS: 1 | US FAERS | |
| 24 | Bladder prolapse | FAERS: 1 | US FAERS | |
| 25 | Blindness | FAERS: 1 | US FAERS | |
| 26 | Bone pain | FAERS: 1 | US FAERS | |
| 27 | Breast tenderness | FAERS: 1 | US FAERS | |
| 28 | Cataract | FAERS: 1 | US FAERS | |
| 29 | Cerebral disorder | FAERS: 1 | US FAERS | |
| 30 | Chest Pain | FAERS: 1 | US FAERS | |
| 31 | Constipation | FAERS: 1 | US FAERS | |
| 32 | Contraindicated product administered | FAERS: 1 | US FAERS | |
| 33 | Cystitis | FAERS: 1 | US FAERS | |
| 34 | Deafness | FAERS: 1 | US FAERS | |
| 35 | Deep Vein Thrombosis | FAERS: 1 | US FAERS | |
| 36 | Disease recurrence | FAERS: 1 | US FAERS | |
| 37 | Disorientation | FAERS: 1 | US FAERS | |
| 38 | Dizziness | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 39 | Drug dose omission | FAERS: 1 | US FAERS | |
| 40 | Emotional disorder | FAERS: 1 | US FAERS | |
| 41 | Endometrial thickening | FAERS: 1 | US FAERS | |
| 42 | Fatigue | FAERS: 1 | US FAERS | |
| 43 | Feeling abnormal | FAERS: 1 | US FAERS | |
| 44 | Hypersensitivity | FAERS: 1 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 45 | Implant site reaction | FAERS: 1 | US FAERS | |
| 46 | Intentional drug misuse | FAERS: 1 | US FAERS | |
| 47 | Lip and/or oral cavity cancer | FAERS: 1 | US FAERS | |
| 48 | Medication Error | FAERS: 1 | US FAERS | |
| 49 | Memory impairment | FAERS: 1 | US FAERS | |
| 50 | Menorrhagia | FAERS: 1 | US FAERS | |
| 51 | Metrorrhagia | FAERS: 1 | US FAERS | |
| 52 | Myocardial Infarction | FAERS: 1 | US FAERS | |
| 53 | Nephrolithiasis | FAERS: 1 | US FAERS | |
| 54 | Nervousness | FAERS: 1 | US FAERS | |
| 55 | Night sweats | FAERS: 1 | US FAERS | |
| 56 | Nipple pain | FAERS: 1 | US FAERS | |
| 57 | Nuchal Rigidity | FAERS: 1 | US FAERS | |
| 58 | Osteopenia | FAERS: 1 | US FAERS | |
| 59 | Pain | FAERS: 1 | US FAERS | |
| 60 | Pallor | FAERS: 1 | US FAERS | |
| 61 | Pancreatic Cyst | FAERS: 1 | US FAERS | |
| 62 | Periarthritis | FAERS: 1 | US FAERS | |
| 63 | Pharmaceutical product complaint | FAERS: 1 | US FAERS | |
| 64 | Porphyria non-acute | FAERS: 1 | US FAERS | |
| 65 | Product quality issue | FAERS: 1 | US FAERS | |
| 66 | Product substitution issue | FAERS: 1 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 67 | Product use issue | FAERS: 1 | US FAERS | |
| 68 | Pulmonary Embolism | FAERS: 1 | US FAERS | |
| 69 | Reaction to drug excipients | FAERS: 1 | US FAERS | |
| 70 | Retinal vascular thrombosis | FAERS: 1 | US FAERS | |
| 71 | Screaming | FAERS: 1 | US FAERS | |
| 72 | Serositis | FAERS: 1 | US FAERS | |
| 73 | Skin irritation | FAERS: 1 | US FAERS | |
| 74 | Therapeutic response unexpected | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 75 | Thrombophlebitis | FAERS: 1 | US FAERS | |
| 76 | Thrombosis | FAERS: 1 | US FAERS | |
| 77 | Ulcer | FAERS: 1 | US FAERS | |
| 78 | Urinary Incontinence | FAERS: 1 | US FAERS | |
| 79 | Vaginal adenocarcinoma | FAERS: 1 | US FAERS | |
| 80 | Vein pain | FAERS: 1 | US FAERS | |
| 81 | Vulvovaginal discomfort | FAERS: 1 | US FAERS | |
| 82 | Vulvovaginal dryness | FAERS: 1 | US FAERS | |
| 83 | Vulvovaginal pain | FAERS: 1 | US FAERS | |
| 84 | Weight decreased | FAERS: 1 | US FAERS | |
| 85 | Wound dehiscence | FAERS: 1 | US FAERS | |
| 86 | nervous system disorder | FAERS: 1 | US FAERS | |
| 87 | Dyspepsia | Canada Vigilance: 1 | Canada Vigilance | |
| 88 | Mood swings | Canada Vigilance: 1 | Canada Vigilance | |
| 89 | Nausea | Canada Vigilance: 2 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120234
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.